Penile Enhancement, Small Penis
Conditions
Keywords
Hyaluronic acid, Small Penis, Penile Enhancement
Brief summary
The investigators aimed to confirm the efficacy and safety of transdermal penis enlargement for 24 weeks after CMDHA0101 injection in subjects who wanted penile enlargement in male patients with small-penis syndrome \*. \*Small-penis syndrome is the anxiety of thinking one's penis is too small - even though it isn't.
Detailed description
This study was designed as a 24-week, randomized, blinded, active control trial. If a subject signing a clinical trial agreement and satisfying the selection / exclusion criteria is enrolled in this clinical trial, he / she will receive the medical device for clinical testing at the baseline time, return to his / her home after the training . At 4 weeks, 12 weeks, and 24 weeks after the application of the medical device for clinical testing at baseline, the safety, penile girth, length, and satisfaction of the subject were evaluated. 24 weeks after application, the clinical trial sponsor (or trustee) retrieves the data necessary for the analysis of results, such as case records, for the purpose of validity and safety evaluation
Interventions
DEVICECMDHA0101
Maximum injection dose : 22 ml
DEVICEPowerFill®
Maximum injection dose : 22 ml
Sponsors
CHA MEDITECH Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Masking description
Subject blind
Eligibility
Sex/Gender
MALE
Age
20 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Men over 20 years old and under 65 years of age 2. In screening, subjects' perception of penile size for dysmenorrhoea syndrome Those who responded with small, small, normal, large, very large 3. Persons who have agreed to discontinue other procedures or treatments for penile enlargement during the course of the trial 4. If the person is circumcised or has not undergone circumcision, A person who does not cover the glans 5. Those who have agreed to abstinence (sexual intercourse, masturbation, etc.) for at least one month after the medical device for clinical trial 6. Those who can understand and follow instructions 7. A person who voluntarily participates in the clinical trial and has agreed in writing to the subject consent form
Exclusion criteria
1. A person who has received anticoagulant or antiplatelet agent within 2 weeks before application of medical device for clinical trial or Those who need to be administered until two weeks after application (However, low-dose aspirin (300 mg / day or less) is permitted. 2. A person who has received a vitamin E preparation, NSAID preparation within 1 week of application of medical device for clinical trial or Those who need to take medicine until 1 week after application 3. Those who have a history of bleeding in past or present time 4. Persons who are adversely affected by excessive penis enlargement, which may adversely affect the operation of the medical device 5. Those who have undergone penis enlargement surgery (fat, alternative dermatologic transplantation) in the past (except for hyaluronic acid or collagen. Two years after transplantation and extension of the penis, such as suprapubic fat preparation and suspension ligament resection In the case of surgery, it is allowed.) 6. Peyronie's disease of the penis (Peyronie's disease) malformation 7. Anaphylaxis or severe allergic symptoms.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The difference in value from the basal value around the penis circumference after using the test device compared to the control device | baseline, 24 weeks | Measured by value difference |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The difference in value from the basal value around the penis circumference after using the test device compared to the control device | baseline, 4 weeks, 12 weeks, 24 weeks | Measured by value difference |
Countries
South Korea
Outcome results
None listed